Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
60 Degrees Pharma survey suggests babesiosis affects up to 3M Americans—vastly more than CDC data—and may underlie millions of chronic fatigue cases.
-
60 Degrees Pharma CEO Geoff Dow, PhD, will discuss babesiosis threats and therapies at the virtual Healing Lyme Summit, April 15–21
-
60 Degrees Pharma partners with Yale to develop tafenoquine for treating and preventing babesiosis, a severe tick-borne disease with limited treatments.
-
60 Degrees Pharmaceuticals (SXTP) reported 140% revenue growth in 2024, driven by Arakoda® sales. Clinical trials and market expansion efforts continue.
-
60 Degrees Pharma (SXTP) announces a 1-for-5 reverse stock split, effective Feb. 24, 2025, to meet Nasdaq's $1.00 minimum bid price requirement.
-
60 Degrees Pharma will import KODATEF® from Australia to ensure U.S. tafenoquine supply, addressing rising ARAKODA® demand.
-
60 Degrees Pharma closed a $1.075M registered direct offering, raising $2.118M YTD to fund operations. H.C. Wainwright & Co. acted as placement agent.
-
60 Degrees Pharma (SXTP) announces a $1.075M registered direct offering, issuing stock and warrants to fund working capital and corporate initiatives.
-
60 Degrees Pharma (Nasdaq: SXTP) closed a $1.043M registered direct offering, issuing common stock and short-term warrants to fund working capital.
-
60 Degrees Pharma (SXTP) announces a $1.043M registered direct offering, issuing stock and warrants to fund working capital and corporate initiatives.